Edgewise Therapeutics (EWTX) Change in Acquisitions & Divestments (2021 - 2026)

Edgewise Therapeutics has reported Change in Acquisitions & Divestments for 6 years, with the latest figure at $4.0 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 73.56% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.4 million (up 301.88% YoY) and the FY2025 annual result came in at $67.4 million, up 326.64% from the prior year.
• Change in Acquisitions & Divestments fell to $4.0 million in Q1 2026 per EWTX's latest filing, from $15.9 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $214.1 million in Q2 2025 and troughed at -$258.3 million in Q4 2023.
• A 5-year average of $17.9 million and a median of $36.9 million in 2022 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2023 and 2025: Change in Acquisitions & Divestments slumped 469.69% in 2023, then jumped 418.28% in 2025.
• Over 5 years, Change in Acquisitions & Divestments stood at $69.9 million in 2022, then plunged by 469.69% to -$258.3 million in 2023, then soared by 101.19% to $3.1 million in 2024, then surged by 418.28% to $15.9 million in 2025, then sank by 75.11% to $4.0 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $4.0 million, $15.9 million, and -$177.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.